Gene therapy strategies for AIDS-related malignancies

Tyler J Curiel, A. Piché, K. Kasono, D. T. Curiel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

AIDS-related malignancies (ARM) include AIDS-defining cancers such as Kaposi's sarcoma, non-Hodgkin's lymphoma and cervical carcinoma. In addition, certain other malignancies are also increased with human immunodeficiency virus (HIV) infection. New antiretroviral agents and better prophylaxis and treatment of HIV-related opportunistic infections are prolonging the lives of HIV-infected individuals. There will thus likely be a continued rise in the incidence and prevalence of ARM in the long term, even if effective antiretroviral and other AIDS-related therapies reduce their appearance in the short term. There are presently no curative regimens for the common ARM, with the possible exception of some lymphomas. Survival is shortened by most, and treatment is often toxic and poorly tolerated. Gene therapies may thus offer a useful adjunct to conventional treatment strategies for selected ARM. Although some gene therapy strategies may work well in the HIV setting, the chronic viral infection, immunodeficient status of the host, the tendency for HIV-infected individuals to have altered drug metabolism and an increased rate of adverse reactions will likely present special challenges. This review summarizes the state-of-the-art in the fledgling field of gene therapy for ARM, and explores areas for future research.

Original languageEnglish (US)
Pages (from-to)1284-1288
Number of pages5
JournalGene Therapy
Volume4
Issue number12
StatePublished - 1997
Externally publishedYes

Fingerprint

Genetic Therapy
Acquired Immunodeficiency Syndrome
HIV
Neoplasms
Virus Diseases
Anti-Retroviral Agents
Kaposi's Sarcoma
Poisons
Opportunistic Infections
Therapeutics
Non-Hodgkin's Lymphoma
Lymphoma
Carcinoma
Incidence
Pharmaceutical Preparations

Keywords

  • AIDS
  • Cervical carcinoma
  • Gene therapy
  • Kaposi's sarcoma
  • Malignancy
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Genetics

Cite this

Curiel, T. J., Piché, A., Kasono, K., & Curiel, D. T. (1997). Gene therapy strategies for AIDS-related malignancies. Gene Therapy, 4(12), 1284-1288.

Gene therapy strategies for AIDS-related malignancies. / Curiel, Tyler J; Piché, A.; Kasono, K.; Curiel, D. T.

In: Gene Therapy, Vol. 4, No. 12, 1997, p. 1284-1288.

Research output: Contribution to journalArticle

Curiel, TJ, Piché, A, Kasono, K & Curiel, DT 1997, 'Gene therapy strategies for AIDS-related malignancies', Gene Therapy, vol. 4, no. 12, pp. 1284-1288.
Curiel TJ, Piché A, Kasono K, Curiel DT. Gene therapy strategies for AIDS-related malignancies. Gene Therapy. 1997;4(12):1284-1288.
Curiel, Tyler J ; Piché, A. ; Kasono, K. ; Curiel, D. T. / Gene therapy strategies for AIDS-related malignancies. In: Gene Therapy. 1997 ; Vol. 4, No. 12. pp. 1284-1288.
@article{bdc48364362c43d086b29575d8396e6f,
title = "Gene therapy strategies for AIDS-related malignancies",
abstract = "AIDS-related malignancies (ARM) include AIDS-defining cancers such as Kaposi's sarcoma, non-Hodgkin's lymphoma and cervical carcinoma. In addition, certain other malignancies are also increased with human immunodeficiency virus (HIV) infection. New antiretroviral agents and better prophylaxis and treatment of HIV-related opportunistic infections are prolonging the lives of HIV-infected individuals. There will thus likely be a continued rise in the incidence and prevalence of ARM in the long term, even if effective antiretroviral and other AIDS-related therapies reduce their appearance in the short term. There are presently no curative regimens for the common ARM, with the possible exception of some lymphomas. Survival is shortened by most, and treatment is often toxic and poorly tolerated. Gene therapies may thus offer a useful adjunct to conventional treatment strategies for selected ARM. Although some gene therapy strategies may work well in the HIV setting, the chronic viral infection, immunodeficient status of the host, the tendency for HIV-infected individuals to have altered drug metabolism and an increased rate of adverse reactions will likely present special challenges. This review summarizes the state-of-the-art in the fledgling field of gene therapy for ARM, and explores areas for future research.",
keywords = "AIDS, Cervical carcinoma, Gene therapy, Kaposi's sarcoma, Malignancy, Non-Hodgkin's lymphoma",
author = "Curiel, {Tyler J} and A. Pich{\'e} and K. Kasono and Curiel, {D. T.}",
year = "1997",
language = "English (US)",
volume = "4",
pages = "1284--1288",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Gene therapy strategies for AIDS-related malignancies

AU - Curiel, Tyler J

AU - Piché, A.

AU - Kasono, K.

AU - Curiel, D. T.

PY - 1997

Y1 - 1997

N2 - AIDS-related malignancies (ARM) include AIDS-defining cancers such as Kaposi's sarcoma, non-Hodgkin's lymphoma and cervical carcinoma. In addition, certain other malignancies are also increased with human immunodeficiency virus (HIV) infection. New antiretroviral agents and better prophylaxis and treatment of HIV-related opportunistic infections are prolonging the lives of HIV-infected individuals. There will thus likely be a continued rise in the incidence and prevalence of ARM in the long term, even if effective antiretroviral and other AIDS-related therapies reduce their appearance in the short term. There are presently no curative regimens for the common ARM, with the possible exception of some lymphomas. Survival is shortened by most, and treatment is often toxic and poorly tolerated. Gene therapies may thus offer a useful adjunct to conventional treatment strategies for selected ARM. Although some gene therapy strategies may work well in the HIV setting, the chronic viral infection, immunodeficient status of the host, the tendency for HIV-infected individuals to have altered drug metabolism and an increased rate of adverse reactions will likely present special challenges. This review summarizes the state-of-the-art in the fledgling field of gene therapy for ARM, and explores areas for future research.

AB - AIDS-related malignancies (ARM) include AIDS-defining cancers such as Kaposi's sarcoma, non-Hodgkin's lymphoma and cervical carcinoma. In addition, certain other malignancies are also increased with human immunodeficiency virus (HIV) infection. New antiretroviral agents and better prophylaxis and treatment of HIV-related opportunistic infections are prolonging the lives of HIV-infected individuals. There will thus likely be a continued rise in the incidence and prevalence of ARM in the long term, even if effective antiretroviral and other AIDS-related therapies reduce their appearance in the short term. There are presently no curative regimens for the common ARM, with the possible exception of some lymphomas. Survival is shortened by most, and treatment is often toxic and poorly tolerated. Gene therapies may thus offer a useful adjunct to conventional treatment strategies for selected ARM. Although some gene therapy strategies may work well in the HIV setting, the chronic viral infection, immunodeficient status of the host, the tendency for HIV-infected individuals to have altered drug metabolism and an increased rate of adverse reactions will likely present special challenges. This review summarizes the state-of-the-art in the fledgling field of gene therapy for ARM, and explores areas for future research.

KW - AIDS

KW - Cervical carcinoma

KW - Gene therapy

KW - Kaposi's sarcoma

KW - Malignancy

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0031467246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031467246&partnerID=8YFLogxK

M3 - Article

C2 - 9472551

AN - SCOPUS:0031467246

VL - 4

SP - 1284

EP - 1288

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 12

ER -